Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 150

Sort by

Sort Order Select

Journal Articles

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Blood (2024) 144 (4): 445–456.

https://doi.org/10.1182/blood.2023022273

Published: 2024

Includes: Supplemental data

Journal Articles

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

Blood (2023) 142 (Supplement 1): 2854.

https://doi.org/10.1182/blood-2023-186277

Published: 2023

Journal Articles

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

Niek G. Van Der Maas, Dimitri Breems, Clara Klerk, Thomas Pabst, Patrycja Gradowska, Bart J. Biemond, Jurgen Kuball, Janine Van Elssen, Otto Visser, Marie-Christiane Vekemans, Carlos Graux, Johan Maertens, H. Berna Beverloo, Peter J. M. Valk, Gert J. Ossenkoppele, Bob Lowenberg, Geert A. Huls, Jan J. Cornelissen, Jurjen Versluis

Blood (2023) 142 (Supplement 1): 724.

https://doi.org/10.1182/blood-2023-180812

Published: 2023

Journal Articles

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD

Hannes Vietzen, Philippe L. Furlano, Jan J. Cornelissen, Georg A. Böhmig, Peter Jaksch, Elisabeth Puchhammer-Stöckl

Blood (2023) 141 (13): 1560–1573.

https://doi.org/10.1182/blood.2022017650

Published: 2023

Includes: Supplemental data

Journal Articles

Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Camille C.B. Kockerols, Peter JM Valk, Nicole M A Blijlevens, Jan J. Cornelissen, Avinash G. Dinmohamed, Inge Geelen, Mels Hoogendoorn, Jeroen J.W.M. Janssen, Laura G.M. Daenen, Bert A. van der Reijden, Peter E. Westerweel

Blood (2022) 140 (Supplement 1): 3887–3888.

https://doi.org/10.1182/blood-2022-168722

Published: 2022

Journal Articles

Impact of Allele-Level HLA-Matching on Outcomes after Double Unrelated Cord Blood Transplantation in Adults with Malignant Diseases

Giancarlo Fatobene, Livia Mariano, Fernanda Volt, Frederico Rafael Moreira, Jan J. Cornelissen, Didier Blaise, Etienne Daguindau, Nathalie Fegueux, Régis Peffault de Latour, Hanadi Rafii, Monica M Rivera-Franco, Chantal Kenzey, Graziana Maria Scigliuolo, Barbara Cappelli, Annalisa Ruggeri, Eliane Gluckman, Vanderson Rocha

Blood (2022) 140 (Supplement 1): 7729–7730.

https://doi.org/10.1182/blood-2022-169032

Published: 2022

Journal Articles

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Sjoerd J.F. Hermans, Yvette Norden, Jurjen Versluis, Anita W. Rijneveld, Okke De Weerdt, Bart J. Biemond, Arjan A. van de Loosdrecht, Lotte E. Van der Wagen, Mar Bellido, Michel Van Gelder, Walter J.F.M. Van der Velden, Dominik Selleslag, Danielle van Lammeren, Vincent H.J. van der Velden, Liesbeth C. de Wreede, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen

Blood (2022) 140 (Supplement 1): 8890–8892.

https://doi.org/10.1182/blood-2022-163055

Published: 2022

Journal Articles

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Niek Van Der Maas, Kazem Nasserinejad, Thomas Pabst, Johan A. Maertens, Dimitri A. Breems, Markus G Manz, Jacqueline Cloos, Gert J. Ossenkoppele, Yngvar Floisand, Patrycja Gradowska, Bob Lowenberg, Gerwin A. Huls, Douwe Postmus, Francesco Pignatti, Jan J. Cornelissen, Jurjen Versluis

Blood (2022) 140 (Supplement 1): 127–129.

https://doi.org/10.1182/blood-2022-158137

Published: 2022

Journal Articles

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Blood (2022) 140 (Supplement 1): 2126–2129.

https://doi.org/10.1182/blood-2022-157684

Published: 2022

Journal Articles

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

Blood (2022) 139 (15): 2347–2354.

https://doi.org/10.1182/blood.2021014472

Published: 2022

Includes: Supplemental data

Journal Articles

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Blood (2021) 138 (Supplement 1): 3937.

https://doi.org/10.1182/blood-2021-147001

Published: 2021

Journal Articles

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Blood (2021) 138 (Supplement 1): 3953.

https://doi.org/10.1182/blood-2021-150892

Published: 2021

Journal Articles

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Arnon Nagler, Myriam Labopin, Jan J. Cornelissen, Edouard Forcade, Patrice Chevallier, Nathalie Fegueux, Jorge Sierra, Hélène Labussière-Wallet, Jennifer Byrne, Thomas Cluzeau, Didier Blaise, Frédéric Baron, Annalisa Ruggeri, Mohamad Mohty, Deborah Desmier

Blood (2021) 138 (Supplement 1): 3964.

https://doi.org/10.1182/blood-2021-144827

Published: 2021

Journal Articles

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Amin T. Turki, Christophe Peczynski, Olaf Penack, Helene Schoemans, Gerard Socie, Christian Reinhardt, Nathalie Fegueux, Didier Blaise, Nicolaus Kröger, Stephan Mielke, Jan J. Cornelissen, Patrice Chevallier, Ibrahim Yakoub-Agha, Edouard Forcade, Grzegorz W Basak, Zinaida Perić

Blood (2021) 138 (Supplement 1): 1809.

https://doi.org/10.1182/blood-2021-147724

Published: 2021

Journal Articles

Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT

Razan Mohty, Abdul Hamid Bazarbachi, Myriam Labopin, Jordi Esteve, Nicolaus Kröger, Jan J. Cornelissen, Didier Blaise, Gerard Socie, Sébastien Maury, Arnold Ganser, Jean-Henri Bourhis, Claude-Eric Bulabois, Ibrahim Yakoub-Agha, Stephanie Nguyen, Patrice Chevallier, Ali Bazarbachi, Arnon Nagler, Mohamad Mohty

Blood (2021) 138 (Supplement 1): 2920.

https://doi.org/10.1182/blood-2021-149794

Published: 2021

Journal Articles

Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1

Blood (2021) 138 (Supplement 1): 2901.

https://doi.org/10.1182/blood-2021-149695

Published: 2021

Journal Articles

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Jaime Sanz Caballer, MD PhD, Annalisa Ruggeri, MD, Jan J. Cornelissen, MD PhD, Hélène Labussière-Wallet, Didier Blaise, MD, Edouard Forcade, MD, Patrice Chevallier, MD PhD, Anna Grassi, MD, Ludmila S Zubarovskaya, MD PhD professor, Jurgen H.E. Kuball, MD PhD, Patrice Ceballos, MD PhD, Fabio Ciceri, MD, Bipin N. Savani, MD, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 5–6.

https://doi.org/10.1182/blood-2020-139362

Published: 2020

Journal Articles

Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Sebastian Giebel, Sr., Myriam Labopin, MD, Mohamed Houhou, Denis Caillot, Jürgen Finke, Sr., MD PhD, Didier Blaise, MD, Nathalie Fegueux, Mark Edward Ethell, MD, Jan J. Cornelissen, MD PhD, Edouard Forcade, MD PhD, Ibrahim Yakoub-Agha, Federico Lussana, MD, Johan Maertens, Jean-Henri Bourhis, Pavel Jindra, MD PhD, Norbert Claude Gorin, Arnon Nagler, MD, Mohamad Mohty, MD PhD

Blood (2020) 136 (Supplement 1): 6–7.

https://doi.org/10.1182/blood-2020-140328

Published: 2020

Journal Articles

Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141757

Published: 2020

Journal Articles

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-137773

Published: 2020

NARROW

Does IPSS-R downstaging before transplantation improve the prognosis of patients with myelodysplastic neoplasms?

Outcome of Intensively Treated Elderly AML Patients Reported to the Harmony Alliance Compares Well to Outcome of Control Patients of the Prospective Randomized HOVON 103 Study in Elderly AML

A Novel Prognostic Model for Patients with Acute Myeloid Leukemia in First Relapse with Improved Prognostic Accuracy

HLA-E–restricted immune responses are crucial for the control of EBV infections and the prevention of PTLD

Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population

Impact of Allele-Level HLA-Matching on Outcomes after Double Unrelated Cord Blood Transplantation in Adults with Malignant Diseases

The HOVON 100 Study in Adult Acute Lymphoblastic Leukemia Re-Analysed By Multi-State Modeling: Benefits and Risks of Clofarabine

Bayesian Inference for Optimization of Interim Analysis in Clinical Trials By Incorporation of Historical Data: Reanalysis of the HOVON AML 132 Clinical Trial

Increased LFS Following Hematopoietic Cell Transplantation As Compared to Conventional Consolidation Therapy in Patients >60 Years with AML in First Complete Remission and a Matched Donor: Results of a Randomized Phase III Study

Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome

A Novel Early Relapse Prediction Score Based on Age, ISS and Disease Status at the Time of Transplant in Patients with Newly Diagnosed Multiple Myeloma. a Study of the EBMT Chronic Malignancies Working Party

Impact of Specific Adverse Cytogenetic Features on Outcomes after Allogeneic Hematopoietic Cell Transplantation in Myelodysplastic Syndrome with Very Poor Risk Cytogenetics: A Study from the Chronic Malignancies Working Party of EBMT

Outcome of Human Umbilical Cord Blood Stem Cell Transplantation (CBT) for Acute Myeloid Leukemia in Patients Achieving First Complete Remission after One Versus Two Induction Courses: A Study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)

Validating a Machine Learning Grading System for Acute Gvhd. a Study on Behalf of the EBMT Transplant Complications Working Party

Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT

Primary Central Nervous System Involvement at Initial Diagnosis Remains an Independent Risk Factor for Relapse in Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplantation in CR1

Outcomes of Allogeneic Hematopoietic Cell Transplantation with Cord Blood Versus Mismatched Unrelated Donor with Post-Transplant Cyclophosphamide in Acute Myeloid Leukemia: An Analysis from the ALWP of the EBMT

Comparison of Reduced Intensity Conditioning - Allogeneic HCT and Autologous HCT for Elderly Patients with Acute Lymphoblastic Leukemia. an Analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

Gvhd and Relapse Free Survival (GRFS) after Allogeneic Transplantation for Idiopathic Severe Aplastic Anemia: An Analysis from the Saawp Data Quality Initiative Program of EBMT

Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm after Breast Cancer: A Study of the Chronic Malignancies Working Party of the EBMT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only